Sunresin expands SPPS resin portfolio for peptide drug research

Sunresin has broadened its solid phase peptide synthesis resin lineup to support pharma and biotech teams working on complex peptide therapeutics. The move aims to improve coupling efficiency, reduce scale-up risk, and strengthen supply and technical support for drug discovery and manufacturing.

Why it matters: - Peptide-based drugs, including GLP-1 receptor agonists and complex cyclic peptides, are driving more demand for reliable solid phase peptide synthesis materials. - Resin performance affects coupling yield, crude purity, reaction time, and scale-up success. - Better solid supports can reduce failed couplings, side reactions, and downstream purification difficulty.

What happened: - Sunresin expanded its SPPS resin portfolio for pharmaceutical research teams worldwide. - The company added specialized solid supports for C-terminal amides, C-terminal acids, and modified peptide sequences. - Sunresin highlighted Rink Amide AM resin as a key product in the expanded lineup. - The company also pointed researchers to its product information page: More information.

The details: - Sunresin’s SPPS resins are designed to improve matrix uniformity and chemical compatibility during peptide synthesis. - The company says the materials are engineered to maintain structural stability through repeated coupling cycles. - Rink Amide AM resin features uniform bead size distribution and consistent substitution levels. - The resin shows controlled swelling in standard organic solvents such as DMF and DCM. - Sunresin says that swelling behavior supports faster reagent movement through the bead network. - The bead structure is built to resist mechanical fragmentation during stirring or shaking. - The portfolio is intended to support work from early sequence screening through peptide library construction without changing core synthetic conditions. - Sunresin says its polymers are structured for batch-to-batch reproducibility.

Between the lines: - The expansion positions Sunresin as more than a resin supplier. - The company is pairing materials with process support, application expertise, and engineering services. - Sunresin says it offers EPC frameworks for large-scale separation and purification plants. - The pitch is aimed at lowering development risk as peptide projects move from lab-scale experiments to pilot and clinical manufacturing. - Sunresin says it hosted an international symposium on peptide and oligonucleotide technologies at its Xi'an headquarters. - The event brought together academic and industrial participants to discuss synthetic methods, automation, and sustainable purification.

What's next: - Sunresin is inviting pharmaceutical companies, biotech firms, contract research organizations, and other partners to evaluate the expanded resin portfolio. - The company is also offering technical test samples and collaboration opportunities in peptide synthesis technology. - More product specifications, technical documentation, and service details are available on the company website: the official website. - Sunresin says its manufacturing and quality systems are built to support global demand and future scale-up needs.

The bottom line: - Sunresin is betting that better resin design, tighter quality control, and hands-on technical support will help peptide drug developers move faster and with less manufacturing risk.